Hikma Pharmaceuticals (HKMPY)
Hikma Pharmaceuticals Statistics
Share Statistics
Hikma Pharmaceuticals has 110.22M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 110.22M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 154.17M |
| Failed to Deliver (FTD) Shares | 17 |
| FTD / Avg. Volume | 4.38% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 15.42 and the forward PE ratio is null. Hikma Pharmaceuticals's PEG ratio is -2.65.
| PE Ratio | 15.42 |
| Forward PE | n/a |
| PS Ratio | 1.77 |
| Forward PS | n/a |
| PB Ratio | 2.4 |
| P/FCF Ratio | 16.82 |
| PEG Ratio | -2.65 |
Enterprise Valuation
Hikma Pharmaceuticals has an Enterprise Value (EV) of 12.19B.
| EV / Sales | 3.9 |
| EV / EBITDA | 16.49 |
| EV / EBIT | 21.61 |
| EV / FCF | 37.04 |
Financial Position
The company has a current ratio of 1.14, with a Debt / Equity ratio of 0.57.
| Current Ratio | 1.14 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 1.77 |
| Debt / FCF | 3.97 |
| Interest Coverage | 6.95 |
Financial Efficiency
Return on Equity is 15.54% and Return on Invested Capital is 12.79%.
| Return on Equity | 15.54% |
| Return on Assets | 6.99% |
| Return on Invested Capital | 12.79% |
| Revenue Per Employee | $329.16K |
| Profits Per Employee | $37.79K |
| Employee Count | 9,500 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.74 |
Taxes
| Income Tax | 93M |
| Effective Tax Rate | 20.44% |
Stock Price Statistics
The stock price has increased by 11.03% in the last 52 weeks. The beta is 0.69, so Hikma Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | 11.03% |
| 50-Day Moving Average | 52.49 |
| 200-Day Moving Average | 51.3 |
| Relative Strength Index (RSI) | 64.58 |
| Average Volume (20 Days) | 388 |
Income Statement
In the last 12 months, Hikma Pharmaceuticals had revenue of 3.13B and earned 359M in profits. Earnings per share was 3.24.
| Revenue | 3.13B |
| Gross Profit | 1.42B |
| Operating Income | 612M |
| Net Income | 359M |
| EBITDA | 739M |
| EBIT | 530M |
| Earnings Per Share (EPS) | 3.24 |
Balance Sheet
The company has 188M in cash and 1.31B in debt, giving a net cash position of -1.12B.
| Cash & Cash Equivalents | 188M |
| Total Debt | 1.31B |
| Net Cash | -1.12B |
| Retained Earnings | 2.36B |
| Total Assets | 5.13B |
| Working Capital | 285M |
Cash Flow
In the last 12 months, operating cash flow was 564M and capital expenditures -235M, giving a free cash flow of 329M.
| Operating Cash Flow | 564M |
| Capital Expenditures | -235M |
| Free Cash Flow | 329M |
| FCF Per Share | 1.49 |
Margins
Gross margin is 45.25%, with operating and profit margins of 19.57% and 11.48%.
| Gross Margin | 45.25% |
| Operating Margin | 19.57% |
| Pretax Margin | 14.55% |
| Profit Margin | 11.48% |
| EBITDA Margin | 23.63% |
| EBIT Margin | 19.57% |
| FCF Margin | 10.52% |
Dividends & Yields
HKMPY pays an annual dividend of $2.54, which amounts to a dividend yield of 2.95%.
| Dividend Per Share | $2.54 |
| Dividend Yield | 2.95% |
| Dividend Growth (YoY) | 2.13% |
| Payout Ratio | 78.88% |
| Earnings Yield | 6.49% |
| FCF Yield | 2.97% |
Analyst Forecast
Currently there are no analyst rating for HKMPY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 3.68 |
| Piotroski F-Score | 6 |